Pediatric burden and seasonality of human metapneumovirus over 5 years in Managua, Nicaragua.
ALRI
community-based
human metapneumovirus
respiratory infection
seasonality
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
26
07
2022
received:
01
06
2022
accepted:
30
07
2022
pubmed:
16
8
2022
medline:
6
10
2022
entrez:
15
8
2022
Statut:
ppublish
Résumé
Human metapneumovirus (hMPV) is an important cause of pediatric respiratory infection. We leveraged the Nicaraguan Pediatric Influenza Cohort Study (NPICS) to assess the burden and seasonality of symptomatic hMPV infection in children. NPICS is an ongoing prospective study of children in Managua, Nicaragua. We assessed children for hMPV infection via real-time reverse-transcription polymerase chain reaction (RT-PCR). We used classical additive decomposition analysis to assess the temporal trends, and generalized growth models (GGMs) were used to estimate effective reproduction numbers. From 2011 to 2016, there were 564 hMPV symptomatic infections, yielding an incidence rate of 5.74 cases per 100 person-years (95% CI 5.3, 6.2). Children experienced 3509 acute lower respiratory infections (ALRIs), of which 160 (4.6%) were associated with hMPV infection. Children under the age of one had 55% of all symptomatic hMPV infections (62/112) develop into hMPV-associated ALRIs and were five times as likely as children over one to have an hMPV-associated ALRI (rate ratio 5.5 95% CI 4.1, 7.4 p < 0.001). Additionally, symptomatic reinfection with hMPV was common. In total, 87 (15%) of all observed symptomatic infections were detected reinfections. The seasonality of symptomatic hMPV outbreaks varied considerably. From 2011 to 2016, four epidemic periods were observed, following a biennial seasonal pattern. The mean ascending phase of the epidemic periods were 7.7 weeks, with an overall mean estimated reproductive number of 1.2 (95% CI 1.1, 1.4). Symptomatic hMPV infection was associated with substantial burden among children in the first year of life. Timing and frequency of symptomatic hMPV incidence followed biennial patterns.
Sections du résumé
BACKGROUND
Human metapneumovirus (hMPV) is an important cause of pediatric respiratory infection. We leveraged the Nicaraguan Pediatric Influenza Cohort Study (NPICS) to assess the burden and seasonality of symptomatic hMPV infection in children.
METHODS
NPICS is an ongoing prospective study of children in Managua, Nicaragua. We assessed children for hMPV infection via real-time reverse-transcription polymerase chain reaction (RT-PCR). We used classical additive decomposition analysis to assess the temporal trends, and generalized growth models (GGMs) were used to estimate effective reproduction numbers.
RESULTS
From 2011 to 2016, there were 564 hMPV symptomatic infections, yielding an incidence rate of 5.74 cases per 100 person-years (95% CI 5.3, 6.2). Children experienced 3509 acute lower respiratory infections (ALRIs), of which 160 (4.6%) were associated with hMPV infection. Children under the age of one had 55% of all symptomatic hMPV infections (62/112) develop into hMPV-associated ALRIs and were five times as likely as children over one to have an hMPV-associated ALRI (rate ratio 5.5 95% CI 4.1, 7.4 p < 0.001). Additionally, symptomatic reinfection with hMPV was common. In total, 87 (15%) of all observed symptomatic infections were detected reinfections. The seasonality of symptomatic hMPV outbreaks varied considerably. From 2011 to 2016, four epidemic periods were observed, following a biennial seasonal pattern. The mean ascending phase of the epidemic periods were 7.7 weeks, with an overall mean estimated reproductive number of 1.2 (95% CI 1.1, 1.4).
CONCLUSIONS
Symptomatic hMPV infection was associated with substantial burden among children in the first year of life. Timing and frequency of symptomatic hMPV incidence followed biennial patterns.
Identifiants
pubmed: 35965382
doi: 10.1111/irv.13034
pmc: PMC9530515
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1112-1121Subventions
Organisme : NIAID NIH HHS
ID : R01 AI143865
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : R01AI149747
Organisme : NIAID NIH HHS
ID : U01 AI088654
Pays : United States
Informations de copyright
© 2022 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
J Chronic Dis. 1982;35(6):437-43
pubmed: 7042727
Lancet Glob Health. 2021 Jan;9(1):e33-e43
pubmed: 33248481
J Med Virol. 2010 Dec;82(12):2092-6
pubmed: 20981798
N Engl J Med. 2013 Feb 14;368(7):633-43
pubmed: 23406028
J Med Virol. 2008 Jun;80(6):1084-9
pubmed: 18428137
Nat Med. 2001 Jun;7(6):719-24
pubmed: 11385510
J Med Virol. 2012 Mar;84(3):511-6
pubmed: 22246840
Epidemiol Infect. 2013 Apr;141(4):827-32
pubmed: 22874773
Influenza Other Respir Viruses. 2018 Jul;12(4):508-513
pubmed: 29288526
J Med Virol. 2011 Mar;83(3):517-24
pubmed: 21264874
PLoS One. 2020 Dec 28;15(12):e0244093
pubmed: 33370354
Pediatr Infect Dis J. 2008 Dec;27(12):1065-8
pubmed: 18978517
J Med Virol. 2009 Oct;81(10):1814-8
pubmed: 19697417
Clin Microbiol Rev. 2011 Oct;24(4):734-54
pubmed: 21976607
Clin Microbiol Rev. 2016 Oct;29(4):795-818
pubmed: 27413096
Infect Genet Evol. 2013 Apr;15:43-52
pubmed: 21292032
BMC Infect Dis. 2019 Aug 30;19(1):757
pubmed: 31470805
Influenza Other Respir Viruses. 2022 Nov;16(6):1112-1121
pubmed: 35965382
Emerg Infect Dis. 2006 Aug;12(8):1263-6
pubmed: 16965711
J Infect Public Health. 2019 May - Jun;12(3):357-363
pubmed: 30573330
J R Soc Interface. 2016 Oct;13(123):
pubmed: 27707909
Influenza Other Respir Viruses. 2021 Jan;15(1):72-80
pubmed: 32881286
Am J Epidemiol. 2014 Nov 1;180(9):865-75
pubmed: 25294601
Pediatr Infect Dis J. 2021 May 1;40(5):479-485
pubmed: 33480663
Emerg Infect Dis. 2005 Jul;11(7):1074-8
pubmed: 16022783
Rev Med Virol. 2020 Jan;30(1):e2090
pubmed: 31788915
J Infect Dis. 2006 Feb 1;193(3):396-403
pubmed: 16388487
Indian J Med Microbiol. 2016 Jan-Mar;34(1):27-32
pubmed: 26776115
J Mol Diagn. 2012 Jan;14(1):61-4
pubmed: 22056628
Science. 2000 Jan 28;287(5453):667-70
pubmed: 10650003
Elife. 2020 Jul 07;9:
pubmed: 32633233
Clin Infect Dis. 2022 May 26;:
pubmed: 35639580
Sci Rep. 2016 Jun 09;6:27730
pubmed: 27279080
J Clin Microbiol. 2005 Mar;43(3):1213-9
pubmed: 15750086
BMC Pediatr. 2019 Oct 10;19(1):345
pubmed: 31601181
Lancet. 2019 Aug 31;394(10200):757-779
pubmed: 31257127
Sci Rep. 2019 Oct 1;9(1):14022
pubmed: 31575919
Clin Infect Dis. 2020 Jun 10;70(12):2683-2694
pubmed: 31353397
Ital J Pediatr. 2015 Apr 18;41:33
pubmed: 25903455
Virology. 2003 Oct 10;315(1):1-9
pubmed: 14592754
J Infect Dis. 2008 Sep 15;198(6):836-42
pubmed: 18680407
Arch Virol. 2013 Feb;158(2):417-24
pubmed: 23074040
Emerg Infect Dis. 2003 Dec;9(12):1626-8
pubmed: 14720409
J Infect Dis. 2003 Dec 15;188(12):1865-7
pubmed: 14673765
N Engl J Med. 2004 Jan 29;350(5):443-50
pubmed: 14749452
BMC Infect Dis. 2015 Nov 09;15:504
pubmed: 26553094
Clin Microbiol Rev. 2017 Apr;30(2):481-502
pubmed: 28179378
Nat Commun. 2022 Mar 4;13(1):1190
pubmed: 35246548
J Infect Dis. 2006 Feb 1;193(3):387-95
pubmed: 16388486
J Infect Dis. 2010 Jun 15;201(12):1890-8
pubmed: 20446850
Influenza Other Respir Viruses. 2014 Jul;8(4):414-21
pubmed: 24761765
Emerg Infect Dis. 2006 Jan;12(1):147-50
pubmed: 16494734
Emerg Infect Dis. 2004 Apr;10(4):700-5
pubmed: 15200863